Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7672)
All Articles published online
|
Publishing Process of This Article
|
Sep 27, 2014 (publication date) through Nov 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669 [PMID: 25276282 DOI: 10.4254/wjh.v6.i9.660] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v6/i9/660.htm |
| Number | Citing Articles |
| 1 |
Laurent Alric, Caroline Besson, Nathanael Lapidus, Juliette Jeannel, Jean-Marie Michot, Patrice Cacoub, Danielle Canioni, Stanislas Pol, Frédéric Davi, Pascaline Rabiega, Loic Ysebaert, Delphine Bonnet, Olivier Hermine, Ming-Lung Yu. Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLOS ONE 2016; 11(10): e0162965 doi: 10.1371/journal.pone.0162965
|
| 2 |
D. Salmon, F. Bani-Sadr, C. Gilbert, E. Rosenthal, M.A. Valantin, A. Simon, D. Neau, P. Morlat, M.A. Loko, L. Wittkop, F. Dabis. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of Clinical Virology 2015; 73: 32 doi: 10.1016/j.jcv.2015.10.010
|
| 3 |
João Paulo Vilela Rodrigues, Maurílio de Souza Cazarim, Silvana Gama Florencio Chachá, Ana de Lourdes Candolo Martinelli, Leonardo Régis Leira Pereira. Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de Saúde Pública 2020; 36(2) doi: 10.1590/0102-311x00036619
|
| 4 |
Javier Salmerón, Carmen Vinaixa, Rubén Berenguer, Juan Manuel Pascasio, Juan José Sánchez Ruano, Miguel Ángel Serra, Ana Gila, Moisés Diago, Manuel Romero-Gómez, José María Navarro, Milagros Testillano, Conrado Fernández, Dolores Espinosa, Isabel Carmona, José Antonio Pons, Francisco Jorquera, Francisco Javier Rodriguez, Ramón Pérez, José Luis Montero, Rafael Granados, Miguel Fernández, Ana Belén Martín, Paloma Muñoz de Rueda, Rosa Quiles, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World Journal of Gastroenterology 2015; 21(30): 9163-9174 doi: 10.3748/wjg.v21.i30.9163
|
| 5 |
Alessandra Mangia, Victor De Ledinghen, François Bailly, Javier Brahm, Jazeps Keiss, Jonas Valantinas, Nele Rasmann, Diethelm Messinger, Fernando Tatsch, Georgios Bakalos, Graham R. Foster. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus 2016; 5(1) doi: 10.1186/s40064-016-3663-6
|
| 6 |
Timothy A. Bach, Kathy Zaiken. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting. American Journal of Health-System Pharmacy 2017; 74(5_Supplement_1): S1 doi: 10.2146/ajhp160567
|
| 7 |
Vanessa Costilla, Neha Mathur, Julio A. Gutierrez. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. Clinics in Liver Disease 2015; 19(4): 641 doi: 10.1016/j.cld.2015.06.005
|
| 8 |
J. Boursier, A. Ducancelle, J. Vergniol, P. Veillon, V. Moal, C. Dufour, J.‐P. Bronowicki, D. Larrey, C. Hézode, F. Zoulim, H. Fontaine, V. Canva, T. Poynard, S. Allam, V. De Lédinghen. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of Viral Hepatitis 2015; 22(12): 1002 doi: 10.1111/jvh.12433
|
| 9 |
Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. Journal of Comparative Effectiveness Research 2017; 6(1): 65 doi: 10.2217/cer-2016-0042
|
| 10 |
Antonia Lepida, Massimo Colombo, Inmaculada Fernandez, Djamal Abdurakhmanov, Paulo Abrao Ferreira, Simone I. Strasser, Petr Urbanek, Alessandra Mangia, José L. Calleja, Wafae Iraqi, Ralph DeMasi, Isabelle Lonjon-Domanec, Christophe Moreno, Heiner Wedemeyer, Vincent Wong. Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLOS ONE 2015; 10(9): e0138503 doi: 10.1371/journal.pone.0138503
|
| 11 |
CLEO Study Group, Antonio Ascione, Luigi Elio Adinolfi, Pietro Amoroso, Angelo Andriulli, Orlando Armignacco, Tiziana Ascione, Sergio Babudieri, Giorgio Barbarini, Michele Brogna, Francesco Cesario, Vincenzo Citro, Ernesto Claar, Raffaele Cozzolongo, Giuseppe D’Adamo, Emilio D’Amico, Pellegrino Dattolo, Massimo De Luca, Vincenzo De Maria, Massimo De Siena, Giuseppe De Vita, Antonio Di Giacomo, Rosanna De Marco, Giorgio De Stefano, Giulio De Stefano, Sebastiano Di Salvo, Raffaele Di Sarno, Nunzia Farella, Laura Felicioni, Basilio Fimiani, Luca Fontanella, Giuseppe Foti, Caterina Furlan, Francesca Giancotti, Giancarlo Giolitto, Tiziana Gravina, Barbara Guerrera, Roberto Gulminetti, Angelo Iacobellis, Michele Imparato, Angelo Iodice, Vincenzo Iovinella, Antonio Izzi, Alfonso Liberti, Pietro Leo, Gennaro Lettieri, Ileana Luppino, Aldo Marrone, Ettore Mazzoni, Vincenzo Messina, Roberto Monarca, Vincenzo Narciso, Lorenzo Nosotti, Adriano Maria Pellicelli, Alessandro Perrella, Guido Piai, Antonio Picardi, Paola Pierri, Grazia Pietromatera, Francesco Resta, Luca Rinaldi, Mario Romano, Angelo Rossini, Maurizio Russello, Grazia Russo, Rodolfo Sacco, Vincenzo Sangiovanni, Antonio Schiano, Antonio Sciambra, Gaetano Scifo, Filomena Simeone, Annarita Sullo, Pierluigi Tarquini, Paolo Tundo, Alfredo Vallone. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology 2016; 8(22): 949-956 doi: 10.4254/wjh.v8.i22.949
|
| 12 |
Perica Davitkov, Apoorva Krishna Chandar, Amy Hirsch, Anita Compan, Marina G. Silveira, Donald D. Anthony, Suzanne Smith, Clare Gideon, Robert A. Bonomo, Yngve Falck-Ytter, Do Young Kim. Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PLOS ONE 2016; 11(10): e0163945 doi: 10.1371/journal.pone.0163945
|
| 13 |
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Revista da Sociedade Brasileira de Medicina Tropical 2018; 51(2): 146 doi: 10.1590/0037-8682-0153-2017
|